ABCF2

Summary

ABCF2 (ATP binding cassette subfamily F member 2, HGNC:71) is a protein-coding gene on chromosome 7q36.1, encoding ATP-binding cassette sub-family F member 2 (Q9UG63).

This gene encodes a member of the ATP-binding cassette (ABC) transporter superfamily. ATP-binding cassette proteins transport various molecules across extra- and intracellular membranes. Alterations in this gene may be involved in cancer progression. Related pseudogenes have been identified on chromosomes 3 and 7.

Source: NCBI Gene 10061 — RefSeq curated summary.

At a glance

• GWAS associations: 10
• Clinical variants (ClinVar): 41 total — 3 pathogenic, 1 likely-pathogenic
• Druggable target: yes
• MANE Select transcript: NM_007189

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:71
Approved symbol	ABCF2
Name	ATP binding cassette subfamily F member 2
Location	7q36.1
Locus type	gene with protein product
Status	Approved
Aliases	EST133090, ABC28, M-ABC1, HUSSY-18
Ensembl gene	ENSG00000033050
Ensembl biotype	protein_coding
OMIM	612510
Entrez	10061

Gene structure

Transcript identifiers

Ensembl transcripts: 21 — 19 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000287844, ENST00000441774, ENST00000468073, ENST00000473874, ENST00000477252, ENST00000889547, ENST00000889548, ENST00000889549, ENST00000889550, ENST00000889551, ENST00000889552, ENST00000889553, ENST00000889554, ENST00000889555, ENST00000889556, ENST00000926792, ENST00000926793, ENST00000926794, ENST00000926795, ENST00000970627, ENST00000970628

RefSeq mRNA: 1 — MANE Select: NM_007189 NM_007189

CCDS: CCDS5923

Canonical transcript exons

ENST00000287844 — 15 exons

Exon	Start	End
ENSE00001354848	151211484	151214191
ENSE00001354863	151227163	151227205
ENSE00003817063	151214879	151215082
ENSE00003817212	151226305	151226500
ENSE00003817476	151215967	151216029
ENSE00003818251	151223678	151223849
ENSE00003819593	151219064	151219159
ENSE00003821046	151215604	151215732
ENSE00003821589	151218561	151218650
ENSE00003822627	151221578	151221680
ENSE00003822729	151222521	151222616
ENSE00003824210	151223932	151224114
ENSE00003825168	151218081	151218191
ENSE00003828022	151218754	151218873
ENSE00003830244	151224776	151224988

Expression profiles

Bgee: expression breadth ubiquitous, 259 present calls, max score 91.89.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 28.0270 / max 155.1186, expressed in 1808 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
86883	28.0270	1808

Top tissues by expression

287 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sural nerve	UBERON:0015488	91.89	gold quality
gastrocnemius	UBERON:0001388	91.45	gold quality
muscle of leg	UBERON:0001383	90.78	gold quality
tibialis anterior	UBERON:0001385	90.51	silver quality
endothelial cell	CL:0000115	88.32	gold quality
right frontal lobe	UBERON:0002810	87.98	gold quality
cortical plate	UBERON:0005343	87.90	gold quality
secondary oocyte	CL:0000655	87.42	gold quality
muscle organ	UBERON:0001630	87.41	gold quality
apex of heart	UBERON:0002098	87.26	gold quality
prefrontal cortex	UBERON:0000451	87.07	gold quality
hindlimb stylopod muscle	UBERON:0004252	87.05	gold quality
Brodmann (1909) area 9	UBERON:0013540	86.62	gold quality
right hemisphere of cerebellum	UBERON:0014890	86.58	gold quality
oocyte	CL:0000023	86.14	gold quality
heart left ventricle	UBERON:0002084	86.14	gold quality
mucosa of transverse colon	UBERON:0004991	86.14	gold quality
cerebellar hemisphere	UBERON:0002245	86.11	gold quality
cerebellar cortex	UBERON:0002129	85.94	gold quality
deltoid	UBERON:0001476	85.93	silver quality
cardiac ventricle	UBERON:0002082	85.80	gold quality
stromal cell of endometrium	CL:0002255	85.72	gold quality
islet of Langerhans	UBERON:0000006	85.66	gold quality
lower esophagus muscularis layer	UBERON:0035833	85.40	gold quality
lower esophagus	UBERON:0013473	85.36	gold quality
left testis	UBERON:0004533	85.35	gold quality
ganglionic eminence	UBERON:0004023	85.34	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	85.12	gold quality
right testis	UBERON:0004534	85.02	gold quality
adenohypophysis	UBERON:0002196	85.01	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.61
E-GEOD-124858	no	155.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

1 targeting ABCF2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-432-5P	98.00	68.13	989

Literature-anchored findings (GeneRIF, showing 6)

• ABCF2 may have a role in progression of clear cell ovarian adenocarcinomas (PMID:16203778)
• Data suggest that ABCF2 protein may be a candidate marker for clear cell adenocarcinomas of the ovary and the uterine corpus and may be important for the pathogenesis of these diseases. (PMID:16996567)
• Among cervical cancer cases, 149 (55.8%) expressed ABCF2. The overall survival was longer in ABCF2-negative than ABCF2-positive cases (PMID:19002184)
• Overexpression of ABCF2 suppressed RVD. (PMID:22252987)
• The NRF2-overexpressing cell line, containing high levels of ABCF2, was more resistant to cisplatin-induced apoptosis compared to its control ovarian cancer cell line; whereas the NRF2 knockdown cell line with low levels of ABCF2, was more sensitive to cisplatin treatment than its control cell line. (PMID:28112439)
• Circular RNA Eps15-homology domain-containing protein 2 induce resistance of renal cell carcinoma to sunitinib via microRNA-4731-5p/ABCF2 axis. (PMID:35412955)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	abcf2a	ENSDARG00000038785
danio_rerio	abcf2b	ENSDARG00000052331
mus_musculus	Abcf2	ENSMUSG00000028953
rattus_norvegicus	Abcf2	ENSRNOG00000010609
drosophila_melanogaster	CG9281	FBGN0030672
caenorhabditis_elegans		WBGENE00012097

Paralogs (2): ABCF3 (ENSG00000161204), ABCF1 (ENSG00000204574)

Protein

Protein identifiers

ATP-binding cassette sub-family F member 2 — Q9UG63 (reviewed: Q9UG63)

Alternative names: Iron-inhibited ABC transporter 2

All UniProt accessions (4): A0A090N7X1, C9JHK9, C9JZV3, Q9UG63

UniProt curated annotations — full annotation on UniProt →

Similarity. Belongs to the ABC transporter superfamily. ABCF family. EF3 subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9UG63-1	1	yes
Q9UG63-2	2

RefSeq proteins (1): NP_009120* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003439	ABC_transporter-like_ATP-bd	Domain
IPR003593	AAA+_ATPase	Domain
IPR017871	ABC_transporter-like_CS	Conserved_site
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR032781	ABC_tran_Xtn	Domain
IPR050611	ABCF	Family

Pfam: PF00005, PF12848

UniProt features (13 total): modified residue 3, domain 2, sequence conflict 2, binding site 2, chain 1, splice variant 1, region of interest 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UG63-F1	83.57	0.45

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (2): 118–125; 430–437

Post-translational modifications (3): 218, 304, 512

Function

Pathways and Gene Ontology

Reactome pathways

6 pathways

ID	Pathway
R-HSA-9818032	NFE2L2 regulating MDR associated enzymes
R-HSA-2262752	Cellular responses to stress
R-HSA-8953897	Cellular responses to stimuli
R-HSA-9711123	Cellular response to chemical stress
R-HSA-9755511	KEAP1-NFE2L2 pathway
R-HSA-9759194	Nuclear events mediated by NFE2L2

MSigDB gene sets: 173 (showing top): ELVIDGE_HYPOXIA_DN, E2F_Q4_01, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, SHEPARD_CRASH_AND_BURN_MUTANT_UP, ROVERSI_GLIOMA_COPY_NUMBER_UP, AP2_Q3, WEI_MYCN_TARGETS_WITH_E_BOX, E2F_Q3, SOX9_B1, WANG_LMO4_TARGETS_DN, GARY_CD5_TARGETS_DN, SCHLOSSER_SERUM_RESPONSE_DN, DODD_NASOPHARYNGEAL_CARCINOMA_UP, AACTTT_UNKNOWN, GFI1_01

GO Biological Process (0):

GO Molecular Function (3): ATP binding (GO:0005524), ATP hydrolysis activity (GO:0016887), nucleotide binding (GO:0000166)

GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-5 pathways:

Category	Pathways
Nuclear events mediated by NFE2L2	1
Cellular responses to stimuli	1
Cellular responses to stress	1
Cellular response to chemical stress	1
KEAP1-NFE2L2 pathway	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
ribonucleoside triphosphate phosphatase activity	1
ATP-dependent activity	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Protein interactions and networks

STRING

3014 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ABCF2	ABCB1	P08183	804
ABCF2	ABCE1	P61221	714
ABCF2	ABCB6	Q9NP58	643
ABCF2	ABCD4	O14678	623
ABCF2	ABCB7	O75027	580
ABCF2	ABCC5	O15440	565
ABCF2	ABCC11	Q96J66	554
ABCF2	ABCG4	Q9H172	554
ABCF2	ABCB8	Q9NUT2	548
ABCF2	ABCC12	Q96J65	524
ABCF2	ABCB9	Q9NP78	522
ABCF2	ABCC2	Q92887	495
ABCF2	ABCG2	Q9UNQ0	484
ABCF2	ABCC10	Q5T3U5	481
ABCF2	ABCA13	Q86UQ4	475

IntAct

84 interactions, top by confidence:

A	B	Type	Score
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
RAF1	CALU	psi-mi:“MI:0914”(association)	0.640
IGF1R	PIK3R2	psi-mi:“MI:2364”(proximity)	0.590
ILK	HAX1	psi-mi:“MI:0914”(association)	0.530
ABCF2	AHCYL1	psi-mi:“MI:0914”(association)	0.530
SNW1	SNRNP200	psi-mi:“MI:0914”(association)	0.530
ABCF2	HADHA	psi-mi:“MI:0915”(physical association)	0.370
ACAD9	NDUFS2	psi-mi:“MI:0914”(association)	0.350
OTUB1		psi-mi:“MI:0914”(association)	0.350
OTUB1	EPM2A	psi-mi:“MI:0914”(association)	0.350
RPL10	RPS6	psi-mi:“MI:0914”(association)	0.350
Nfyc	BDP1	psi-mi:“MI:0914”(association)	0.350
PPP5C	PSEN2	psi-mi:“MI:0914”(association)	0.350
Uso1	SLC30A6	psi-mi:“MI:0914”(association)	0.350
Mis12	CTNNB1	psi-mi:“MI:0914”(association)	0.350
Smc1a	PDS5B	psi-mi:“MI:0914”(association)	0.350
TM9SF4		psi-mi:“MI:0914”(association)	0.350
NPM1	RPSA	psi-mi:“MI:0914”(association)	0.350
MAD2L1	MAD1L1	psi-mi:“MI:0914”(association)	0.350
JUN	TPM3	psi-mi:“MI:0914”(association)	0.350
HSCB	RBP5	psi-mi:“MI:0914”(association)	0.350
KSR1	FBLL1	psi-mi:“MI:0914”(association)	0.350
KSR1	DDX39A	psi-mi:“MI:0914”(association)	0.350
KSR1		psi-mi:“MI:0914”(association)	0.350
BCAR1	MYO1C	psi-mi:“MI:0914”(association)	0.350

BioGRID (253): ABCF2 (Affinity Capture-MS), ABCF2 (Affinity Capture-RNA), ABCF2 (Affinity Capture-RNA), ABCF2 (Affinity Capture-RNA), ABCF2 (Affinity Capture-MS), ABCF2 (Affinity Capture-MS), ABCF2 (Affinity Capture-MS), ABCF2 (Affinity Capture-MS), ABCF2 (Affinity Capture-MS), ABCF2 (Co-fractionation), ABCF2 (Co-fractionation), ABCF2 (Co-fractionation), ABCF2 (Co-fractionation), ABCF2 (Co-fractionation), ABCF2 (Co-fractionation)

ESM2 similar proteins: A0A0D1CLQ4, A0A139AVY4, A9X4T1, B9FK36, C5E4D9, D0MYB4, G5EES6, J9VQZ9, O14134, O42943, O59672, O93796, O94489, P06625, P08240, P16521, P16638, P25997, P29551, P40024, P43535, P53396, P53585, P53978, Q08972, Q2KJA2, Q2TCH3, Q32PF2, Q3MHE8, Q4HY71, Q5KIM6, Q5R9Z5, Q66H39, Q6MG08, Q75EV6, Q767L0, Q7YR37, Q8H0V6, Q8K268, Q8NE71

Diamond homologs: A0A0H2VBH0, A0A0H2VFI8, A0KPH6, A1AC19, A1B9H9, A1JRI2, A1U776, O05519, O06476, O31716, O34512, O34631, O42943, O59672, P0A9U3, P0A9U4, P0A9U5, P0A9W3, P0A9W4, P0A9W5, P0A9X1, P0A9X2, P0A9X3, P12622, P25256, P40024, P43535, P43672, P44808, P45127, P57403, P63389, P63390, P9WQK2, P9WQK3, Q0I4A9, Q0T3U8, Q0TGX4, Q0VTB6, Q1C1S0

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 117 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
positive regulation of MAPK cascade	9	7.6×	3e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

41 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	3
Likely pathogenic	1
Uncertain significance	20
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (4)

Variant ID	HGVS	Classification
1330211	GRCh37/hg19 7q36.1(chr7:150745923-152373214)x1	Pathogenic
145486	GRCh38/hg38 7q36.1-36.2(chr7:151214163-153187462)x1	Pathogenic
527120	NC_000007.13:g.(?150642433)(151573725_?)del	Pathogenic
149569	GRCh38/hg38 7q36.1-36.2(chr7:150113232-154162779)x3	Likely pathogenic

SpliceAI

2217 predictions. Top by Δscore:

Variant	Effect	Δscore
7:151214187:GCAAC:G	acceptor_gain	1.0000
7:151214188:CAAC:C	acceptor_gain	1.0000
7:151214188:CAACC:C	acceptor_gain	1.0000
7:151214189:AAC:A	acceptor_gain	1.0000
7:151214190:AC:A	acceptor_gain	1.0000
7:151214191:CC:C	acceptor_gain	1.0000
7:151214192:C:CC	acceptor_gain	1.0000
7:151214873:CCTCA:C	donor_loss	1.0000
7:151214877:AC:A	donor_loss	1.0000
7:151214878:CC:C	donor_loss	1.0000
7:151214878:CCTG:C	donor_gain	1.0000
7:151214919:C:CT	donor_gain	1.0000
7:151214993:C:CT	acceptor_gain	1.0000
7:151215601:GAC:G	donor_loss	1.0000
7:151215603:C:CT	donor_loss	1.0000
7:151215642:T:TA	donor_gain	1.0000
7:151215728:AAATG:A	acceptor_gain	1.0000
7:151215729:AATG:A	acceptor_gain	1.0000
7:151215730:ATG:A	acceptor_gain	1.0000
7:151215731:TG:T	acceptor_gain	1.0000
7:151215731:TGCTA:T	acceptor_loss	1.0000
7:151215732:GCTAC:G	acceptor_loss	1.0000
7:151215733:C:CC	acceptor_gain	1.0000
7:151215961:CTGTA:C	donor_loss	1.0000
7:151215962:TGTA:T	donor_loss	1.0000
7:151215963:GTAC:G	donor_loss	1.0000
7:151215964:TACC:T	donor_loss	1.0000
7:151215965:A:C	donor_loss	1.0000
7:151215966:CCTG:C	donor_loss	1.0000
7:151215984:T:C	donor_gain	1.0000

AlphaMissense

4117 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:151214889:A:G	L575P	1.000
7:151214898:T:A	D572V	1.000
7:151214898:T:C	D572G	1.000
7:151214898:T:G	D572A	1.000
7:151214900:A:C	H571Q	1.000
7:151214900:A:T	H571Q	1.000
7:151214902:G:C	H571D	1.000
7:151214903:G:C	S570R	1.000
7:151214903:G:T	S570R	1.000
7:151214905:T:G	S570R	1.000
7:151214947:C:G	A556P	1.000
7:151214949:A:G	L555P	1.000
7:151214970:T:A	D548V	1.000
7:151214973:A:G	L547P	1.000
7:151214978:A:C	N545K	1.000
7:151214978:A:T	N545K	1.000
7:151214985:G:T	P543H	1.000
7:151214987:T:A	E542D	1.000
7:151214987:T:G	E542D	1.000
7:151214988:T:A	E542V	1.000
7:151214988:T:C	E542G	1.000
7:151214988:T:G	E542A	1.000
7:151214989:C:T	E542K	1.000
7:151214991:T:A	D541V	1.000
7:151214992:C:G	D541H	1.000
7:151215030:G:T	A528D	1.000
7:151215054:C:A	G520V	1.000
7:151215054:C:T	G520E	1.000
7:151215055:C:A	G520W	1.000
7:151215055:C:G	G520R	1.000

dbSNP variants (sampled 300 via entrez): RS1000038159 (7:151217529 G>A), RS1000146707 (7:151225174 C>G), RS1000374572 (7:151211129 C>T), RS1000560000 (7:151228216 C>T), RS1000831940 (7:151218638 A>C), RS1001022204 (7:151212767 A>G), RS1001026718 (7:151222058 A>C), RS1001039489 (7:151215888 C>T), RS1001112917 (7:151215538 C>A,G,T), RS1001251641 (7:151225418 C>T), RS1001438379 (7:151211902 C>T), RS1001592735 (7:151220725 T>C), RS1001765685 (7:151217876 T>A,G), RS1001965499 (7:151227174 G>A), RS1002092332 (7:151214267 C>A,T)

Disease associations

OMIM: gene MIM:612510 | disease phenotypes: MIM:617768

GenCC curated gene-disease

Mondo (2): Kleefstra syndrome 2 (MONDO:0054701), long QT syndrome (MONDO:0002442)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

10 associations (top):

Study	Trait	p-value
GCST001848_161	IgG glycosylation	2.000000e-10
GCST001848_453	IgG glycosylation	2.000000e-09
GCST001848_557	IgG glycosylation	1.000000e-09
GCST001848_60	IgG glycosylation	7.000000e-06
GCST001848_603	IgG glycosylation	6.000000e-10
GCST003476_9	Eyebrow thickness	7.000000e-06
GCST007691_24	Femoral neck bone mineral density	7.000000e-09
GCST008758_66	Pre-treatment viral load in HIV-1 infection	4.000000e-17
GCST008839_24	Height	1.000000e-09
GCST009860_4	IgG N-glycosylation phenotypes (multivariate analysis)	2.000000e-22

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0005193	serum IgG glycosylation measurement
EFO:0007785	femoral neck bone mineral density
EFO:0010125	viral load

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D008133	Long QT Syndrome	C14.280.067.565; C14.280.123.625; C16.131.240.400.715; C23.550.073.547

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6067160 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.26	Kd	5468	nM	CHEMBL3752910
5.26	ED50	5468	nM	CHEMBL3752910

PubChem BioAssay actives

1 with measured affinity, of 2 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149821: Binding affinity to human ABCF2 incubated for 45 mins by Kinobead based pull down assay	kd	5.4678	uM

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects expression, decreases expression	3
Nickel	decreases expression, increases expression	3
bisphenol A	affects expression, decreases expression	2
aristolochic acid I	increases expression	1
bisphenol F	increases expression	1
TAK-243	decreases sumoylation	1
uranyl acetate	affects expression	1
deoxynivalenol	increases expression	1
quercitrin	increases expression	1
cobaltous chloride	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	decreases expression, increases response to substance	1
NSC 689534	affects binding, increases expression	1
Air Pollutants, Occupational	decreases expression	1
Arsenic	affects methylation	1
Benzo(a)pyrene	increases methylation	1
Copper	affects binding, increases expression	1
Dichlorodiphenyl Dichloroethylene	increases expression	1
Estradiol	increases expression	1
Ethyl Methanesulfonate	decreases expression	1
Formaldehyde	increases expression	1
Hydrogen Peroxide	affects expression	1
Ivermectin	decreases expression	1
Methotrexate	decreases expression	1
Methyl Methanesulfonate	decreases expression	1
Ribonucleotides	affects binding	1
Rotenone	decreases expression	1
Sarin	decreases expression, increases expression	1
Smoke	decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5652863	Binding	Binding affinity to human ABCF2 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2R3	Abcam HEK293T ABCF2 KO	Transformed cell line	Female

Clinical trials (associated diseases)

66 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT02513940	PHASE4	COMPLETED	Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes
NCT03834883	PHASE4	COMPLETED	Reducing the Risk of Drug-Induced QT Interval Lengthening in Women
NCT04169100	PHASE4	UNKNOWN	Novel Form of Acquired Long QT Syndrome
NCT04675788	PHASE4	COMPLETED	Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening
NCT01648205	PHASE2	COMPLETED	Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients
NCT02412709	PHASE2	UNKNOWN	Long QT Syndrome Screening in Newborns
NCT04581408	PHASE2	COMPLETED	Mutation-specific Therapy for the Long QT Syndrome
NCT00316459	PHASE1	COMPLETED	Study Evaluating the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects
NCT01849003	PHASE1	COMPLETED	Study of the Effect of GS-6615 in Subjects With LQT-3
NCT02365532	PHASE1	COMPLETED	Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults
NCT02412098	PHASE1	COMPLETED	Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function
NCT02441829	PHASE1	COMPLETED	Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function
NCT05759962	PHASE1	COMPLETED	Phase 1 Study of LQT-1213 in Healthy Adults
NCT05906732	PHASE1/PHASE2	TERMINATED	Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2).
NCT00005176	Not specified	COMPLETED	Long QT Syndrome-Population Genetics and Cardiac Studies
NCT00005250	Not specified	COMPLETED	Linkage Study of Long QT Syndrome In An Amish Kindred
NCT00005367	Not specified	COMPLETED	Epidemiology of Long QTand Asian Sudden Death in Sleep
NCT00221832	Not specified	UNKNOWN	Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases
NCT00292032	Not specified	COMPLETED	Registry of Unexplained Cardiac Arrest
NCT00335036	Not specified	TERMINATED	Pediatric Lead Extractability and Survival Evaluation (PLEASE)
NCT00399412	Not specified	COMPLETED	ECG Signal Collection From Long QT Syndrome, Wide QRS Complexes, Heart Failure, and Cardiac Resynchronization Patients
NCT00488254	Not specified	COMPLETED	The Long QT Syndrome in Pregnancy
NCT00588965	Not specified	COMPLETED	Effect of Beta-blocker Therapy on QTc Response in Exercise and Recovery in Normal Subjects
NCT01705925	Not specified	COMPLETED	Multicenter Evaluation of Children and Young Adults With Genotype Positive Long QT Syndrome
NCT01903564	Not specified	COMPLETED	Fetal and Neonatal Magnetophysiology
NCT02082431	Not specified	COMPLETED	Determine the Incidence of Long QT Amongst a Large Cohort of Subjects Diagnosed With Unilateral or Bilateral Sensorineural Hearing Loss.
NCT02413450	Not specified	ENROLLING_BY_INVITATION	Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias
NCT02425189	Not specified	COMPLETED	The Canadian National Long QT Syndrome Registry
NCT02439645	Not specified	TERMINATED	A Registry to Determine the Clinical and Genetic Risk Factors for Torsade De Pointes
NCT02439658	Not specified	UNKNOWN	Genetics of QT Prolongation With Antiarrhythmics
NCT02549664	Not specified	COMPLETED	Exercise in Genetic Cardiovascular Conditions
NCT02581241	Not specified	COMPLETED	Abnormal QT-Response to the Sudden Tachycardia Provoked by Standing in Individuals With Drug-induced Long QT Syndrome
NCT02680080	Not specified	COMPLETED	Effect of Grapefruit on QT Interval in Healthy Volunteers and Patients With Congenital Long QT Syndrome
NCT02775513	Not specified	UNKNOWN	Metabolism of Patients With Genetically Caused Cardiac Arrhythmia
NCT02814981	Not specified	UNKNOWN	Hydroxyzine and Risk of Prolongation of QT Interval
NCT02876380	Not specified	COMPLETED	Prospective Identification of Long QT Syndrome in Fetal Life
NCT03182777	Not specified	COMPLETED	Safety of Local Dental Anesthesia in Patients With Cardiac Channelopathies
NCT03544918	Not specified	COMPLETED	Prevalence of Congenital Long QT Syndrome and Acquired QT Prolongation in a Hospital Cohort
NCT03642405	Not specified	UNKNOWN	Drug-induced Repolarization ECG Changes
NCT03678311	Not specified	COMPLETED	Long QT Syndrome and Sleep Apnea